This is a phase II precision medicine cancer trial with nearly 40 treatment arms. See study details. Patients with advanced solid tumors, lymphomas, or myeloma may be eligible, once they have progressed on standard treatment for their cancer or if they have a rare cancer for which there is no standard treatment. Some arms have exceptions. Each arm targets a unique gene abnormality known to drive cancer growth. Many of these driver mutations occur only rarely in patients, as shown by the posted frequency rates. These are the rates found in the first 6,000 patients tested in this trial. See the table below for the open treatment arms.

Total accrual: 1199 as of 06/11/2022

http://ecog-acrin.org/trials/nci-match-eay131

For more information: Cincinnati Children’s Division of Hematology / Oncology | Phone: 513-636-2799 | Emailcancer@cchmc.org

 

TARGET

STUDY / ID

ACCRUAL

AGENT

DISEASE EXCEPTIONS

DATE ACTIVATED

STATUS

BRAF V600E or V600K mutations
(0.69% frequency)

H

50 (7)

Taflinar® (dabrafenib) and Mekinist™ (trametinib)

Colorectal cancer, melanoma, non-small cell lung cancer, or thyroid cancer

10/02/2020

OPEN

LAG-3 expression with MMR deficiency
(1.51% frequency)

Z1M

35 (0)

relatlimab + Opdivo® (nivolumab)

Active melanoma

04/19/2021

OPEN